HONG KONG – Hong Kong-based companies Aptorum Group Ltd. and Aeneas Capital Ltd. have signed a $90 million deal with Singapore-based A*ccelerate Technologies Pte Ltd. to develop ventures in the health care and life sciences sector.
HONG KONG – When it comes to innovation in China, the largest companies top the rankings. The annual Clarivate Analytics Top 100 Chinese Innovators list was dominated by big conglomerates such as Fosun International Ltd. and China Resources (Holdings) Co. Ltd. Travis Hu, general manager of Clarivate Life Sciences Business for greater China, said that big corporations have certain given advantages when it comes to drug discovery.
HONG KONG – South Korean biotech company Samsung Bioepis Co. Ltd. has entered a licensing agreement with China's 3Sbio Inc. to expand its biosimilars business to mainland China. The agreement covers multiple biosimilar candidates from the Incheon-based Samsung Bioepis, including SB-8, a biosimilar to blockbuster anti-VEGF antibody Avastin (bevacizumab, Genentech Inc./Roche Holding AG) that is undergoing phase III trials.
HONG KONG – South Korean biotech company Samsung Bioepis Co. Ltd. has entered a licensing agreement with China's 3Sbio Inc. to expand its biosimilars business to mainland China. The agreement covers multiple biosimilar candidates from the Incheon-based Samsung Bioepis, including SB-8, a biosimilar to blockbuster anti-VEGF antibody Avastin (bevacizumab, Genentech Inc./Roche Holding AG) that is undergoing phase III trials.
HONG KONG – Amid renewed interest in CD47 as an immuno-oncology target, Innovent Biologics Inc., of Suzhou, China, has received IND approval in China to start clinical trials of its monoclonal antibody (MAb), IBI-188. To further get ahead in the anti-CD47 race, Innovent will conduct clinical trials on IBI-188 at home and abroad simultaneously.
HONG KONG – Amid renewed interest in CD47 as an immuno-oncology target, Innovent Biologics Inc., of Suzhou, China, has received IND approval in China to start clinical trials of its monoclonal antibody (MAb), IBI-188. To further get ahead in the anti-CD47 race, Innovent will conduct clinical trials on IBI-188 at home and abroad simultaneously.
HONG KONG – Emerging biotech companies can start submitting their formal listing applications in Hong Kong next month as the Stock Exchange of Hong Kong (HKEX) said that proposed new rules to broaden its listing regime will come into effect on April 30.
HONG KONG – Japan's Carna Biosciences Inc. and Sumitomo Dainippon Pharma Co. Ltd. signed an agreement potentially worth about $100 million to work together on the research, development and commercialization of novel kinase inhibitors, focusing on psychiatric and neurological disorders.
